Not available
Quote | Adicet Bio Inc. (NASDAQ:ACET)
Last: | $1.29 |
---|---|
Change Percent: | 2.29% |
Open: | $1.28 |
Close: | $1.29 |
High: | $1.31 |
Low: | $1.245 |
Volume: | 551,770 |
Last Trade Date Time: | 06/11/2024 03:00:00 am |
News | Adicet Bio Inc. (NASDAQ:ACET)
2024-06-05 07:45:31 ET More on Adicet Bio Adicet Bio: Microcap With A High Risk To Reward Ratio Adicet Bio GAAP EPS of -$0.69 beats by $0.01 Seeking Alpha’s Quant Rating on Adicet Bio Historical earnings data for Adicet Bio Financial informatio...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potentia...
Message Board Posts | Adicet Bio Inc. (NASDAQ:ACET)
Subject | By | Source | When |
---|---|---|---|
AviseAnalytics: 7 REASONS TO PUT ADICET BIO ON YOUR WATCHLIST! $ACET Adicet Bio (NASDAQ: ACET) i | AviseAnalytics | investorshangout | 01/24/2022 12:25:33 PM |
No sell off...guess I bet wrong | masterofdisaster | investorshub | 12/08/2021 7:41:01 PM |
Phase 1's usually suck wind, I lost $80K | TheFinalCD | investorshub | 12/08/2021 2:58:31 PM |
It was weird....I think the MMs drop this | masterofdisaster | investorshub | 12/08/2021 12:07:16 PM |
whats weird is the rally after the offering | TheFinalCD | investorshub | 12/08/2021 4:10:48 AM |
News, Short Squeeze, Breakout and More Instantly...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potentia...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferi...
On track to initiate Phase 1 clinical trial evaluating ADI-001 in lupus nephritis in 2Q 2024 Presented promising preclinical data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting; on track to file investigational new drug (IND) in renal cell carcinoma in ...